Published March 1, 2016 | Version v1
Journal article

Value of Magnetic Resonance Imaging Without or With Applicator in Place for Target Definition in Cervix Cancer Brachytherapy

  • 1. Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna (Austria)
  • 2. Department of Radiotherapy, Comprehensive Cancer Center, Medical University of Vienna, Vienna (Austria)
  • 3. Department of Radiation Oncology, Gran Canaria University Hospital, Las Palmas de Gran Canaria (Spain)
  • 4. Institute of Physics and Technology, Tomsk Polytechnic University, Tomsk Oblast (Russian Federation)
  • 5. Department of Clinical Oncology, Medical University of Alexandria, Alexandria (Egypt)

Description

Purpose: To define, in the setting of cervical cancer, to what extent information from additional pretreatment magnetic resonance imaging (MRI) without the brachytherapy applicator improves conformity of CT-based high-risk clinical target volume (CTVHR) contours, compared with the MRI for various tumor stages (International Federation of Gynecology and Obstetrics [FIGO] stages I-IVA). Methods and Materials: The CTVHR was contoured in 39 patients with cervical cancer (FIGO stages I-IVA) (1) on CT images based on clinical information (CTVHR-CTClinical) alone; and (2) using an additional MRI before brachytherapy, without the applicator (CTVHR-CTpre-BT MRI). The CT contours were compared with reference contours on MRI with the applicator in place (CTVHR-MRIref). Width, height, thickness, volumes, and topography were analyzed. Results: The CT-MRIref differences hardly varied in stage I tumors (n=8). In limited-volume stage IIB and IIIB tumors (n=19), CTVHR-CTpre-BT MRI–MRIref volume differences (2.6 cm3 [IIB], 7.3 cm3 [IIIB]) were superior to CTVHR-CTClinical–MRIref (11.8 cm3 [IIB], 22.9 cm3 [IIIB]), owing to significant improvement of height and width (P<.05). In advanced disease (n=12), improved agreement with MR volume, width, and height was achieved for CTVHR-CTpre-BT MRI. In 5 of 12 cases, MRIref contours were partly missed on CT. Conclusions: Pre-BT MRI helps to define CTVHR before BT implantation appropriately, if only CT images with the applicator in place are available for BT planning. Significant improvement is achievable in limited-volume stage IIB and IIIB tumors. In more advanced disease (extensive IIB to IVA), improvement of conformity is possible but may be associated with geographic misses. Limited impact on precision of CTVHR-CT is expected in stage IB tumors.

Availability note (English)

Available from http://dx.doi.org/10.1016/j.ijrobp.2015.09.023

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2015.09.023;
PII
S0360-3016(15)26479-6;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
94
Journal Issue
3
Journal Page Range
p. 588-597
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
48093705
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BRACHYTHERAPY; COMPUTERIZED TOMOGRAPHY; IMAGES; NEOPLASMS; NMR IMAGING
Descriptors DEC
DIAGNOSTIC TECHNIQUES; DISEASES; MEDICINE; NUCLEAR MEDICINE; RADIOLOGY; RADIOTHERAPY; THERAPY; TOMOGRAPHY

Optional Information

Copyright
Copyright (c) 2016 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.